Treatment for Patients with BRCA Mutation | Rubraca® (rucaparib) tablets

Rubraca is a treatment option for women who have ovarian cancer with a BRCA mutation and have finished at least 2 chemotherapy medicines.

 

Rubraca is a prescription medicine used for women with ovarian cancer who:

  • Have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic) and

  • Have received previous treatment with 2 or more prior chemotherapy medicines for their cancer

Your doctor will perform a test to make sure Rubraca is right for you. It is not known if Rubraca is safe and effective in children. Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit.

BRCA=Breast Cancer susceptibility gene.

Go back

What is a BRCA mutation and how does it impact the risk of ovarian cancer?

BRCA stands for Breast Cancer susceptibility gene. Everyone has BRCA1 and BRCA2 genes, which play an important role in normal day-to-day functions of cells.

Some women, however, may have changes in their BRCA genes, called mutations. BRCA mutations increase the likelihood of developing ovarian cancer.
About 1 in 4 women with ovarian cancer may have a BRCA mutation; this is known as being BRCA mutation positive (BRCAmut+).

Women With Ovarian Cancer

Women with Ovarian cancer

BRCA=Breast Cancer susceptibility gene.

Go back

How did I get this mutation?

Some women are born with a BRCA mutation that they have inherited from one of their parents (this is known as a germline mutation). For other women, mutations in BRCA are acquired spontaneously during their lives without an obvious cause (this is known as a somatic mutation).

If you're BRCA mutation positive (BRCAmut+), you have the BRCA mutation either by inheriting it or by acquiring it spontaneously.

Inherited BRCA mutations are found in every cell of the body and can be passed down to children. In contrast, BRCA mutations that are acquired spontaneously are only found in the tumor cells and are not passed down to children.

Women two

Knowing your BRCA status may help your doctor select an appropriate treatment for you

Testing your tumor cells may help your doctor understand what is causing your cancer to grow. Knowing this may then help your doctor choose a treatment.

A BRCA mutation may affect the way ovarian cancer responds to treatment. Knowing if you're BRCA mutation positive (BRCAmut+) may inform you and your doctor's treatment decisions. If you’re BRCA mutation positive, you may respond to a type of treatment called a poly (ADP-ribose) polymerase, or PARP, inhibitor.

Rubraca is a PARP inhibitor that may help some women with BRCA mutation–positive advanced ovarian cancer who have received previous treatment with 2 or more chemotherapy medicines for their cancer.

Go back

What are the possible benefits of taking Rubraca?

The effectiveness of Rubraca was evaluated in 106 women from 2 clinical studies. In women with BRCA mutation–positive (BRCAmut+) advanced ovarian cancer who had received at least 2 prior chemotherapy medicines.

 

As reported by the studies' doctors:

More than half of women saw their tumors shrink with Rubraca treatment

  • 54% of patients had a response with Rubraca
  • 9% had a complete response and 45% had a partial response with Rubraca. A complete response is not the same thing as a cure
  • Not all women saw their tumors shrink or responded to Rubraca treatment
54percent
Go back

What is the most important information I should know about Rubraca?

Important Information

Rubraca may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your doctor will stop treatment with Rubraca.

Symptoms of low blood cell counts are common during treatment with Rubraca, but can be a sign of serious problems, including MDS or AML.

Go back

Discover how Rubraca may help maintain the response to platinum-based chemotherapy

Maintenhance Learn more

Get support through Rubraca Connections

Rubraca Connections Learn more

INDICATIONS

What is Rubraca?

Rubraca® (rucaparib) tablets are a prescription medicine used for:

  • the maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
  • the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children. 

SELECT IMPORTANT SAFETY INFORMATION

Read full

warning Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

warning Symptoms of low blood cell counts are common during treatment with Rubraca but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:

  • weakness
  • weight loss
  • fever
  • frequent infections
  • blood in urine or stool
  • shortness of breath
  • feeling very tired
  • bruising or bleeding more easily

warning Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve. 

warning Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:

warning

  • are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca.
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant.

warning

  • are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.

warning Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 

warning  While taking Rubraca, avoid spending time in sunlight.  Rubraca can make your skin sensitive to the sun (photosensitivity).  You may burn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

warning The most common side effects of Rubraca include:

  • nausea 
  • tiredness or weakness
  • vomiting
  • decrease in hemoglobin (anemia)
  • changes in how food tastes
  • constipation
  • decrease in appetite 
  • diarrhea
  • low blood cell counts
  • mouth sores
  • upper respiratory tract infection
  • shortness of breath
  • rash
  • changes in liver or kidney function blood tests
  • stomach (abdomen) pain
  • increased cholesterol levels

warning These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

warning  You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.

INDICATIONS

What is Rubraca?

Rubraca® (rucaparib) tablets are a prescription medicine used for:

  • the maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy
  • the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure Rubraca is right for you

It is not known if Rubraca is safe and effective in children. 

SELECT IMPORTANT SAFETY INFORMATION

Read full

warning Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

warning Symptoms of low blood cell counts are common during treatment with Rubraca but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with Rubraca:

  • weakness
  • weight loss
  • fever
  • frequent infections
  • blood in urine or stool
  • shortness of breath
  • feeling very tired
  • bruising or bleeding more easily

warning Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve. 

warning Before you take Rubraca, tell your healthcare provider about all of your medical conditions, including if you:

warning

  • are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca.
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca.
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant.

warning

  • are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time.

warning Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. 

warning  While taking Rubraca, avoid spending time in sunlight.  Rubraca can make your skin sensitive to the sun (photosensitivity).  You may burn more easily during treatment with Rubraca. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

warning The most common side effects of Rubraca include:

  • nausea 
  • tiredness or weakness
  • vomiting
  • decrease in hemoglobin (anemia)
  • changes in how food tastes
  • constipation
  • decrease in appetite 
  • diarrhea
  • low blood cell counts
  • mouth sores
  • upper respiratory tract infection
  • shortness of breath
  • rash
  • changes in liver or kidney function blood tests
  • stomach (abdomen) pain
  • increased cholesterol levels

warning These are not all of the possible side effects of Rubraca. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

warning  You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.